Pharmacokinetics and pharmacodynamics of warfarin when coadministered with pentosan polysulfate sodium

Journal of Clinical Pharmacology

Volumn 45, Issue 8, 2005, Pages 919-926

  Modi, Nishit B ^a   Kell, Sherron ^a   Simon, Mary ^a   Vargas, Ramon ^b  

^a ALZA CORPORATION   (United States)

^b MDS Inc   (Canada)

Author keywords

Pentosan polysulfate sodium; Pharmacodynamics; Pharmacokinetics; Warfarin

Indexed keywords

PENTOSAN POLYSULFATE; PLACEBO; WARFARIN;

ANALYSIS OF VARIANCE; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; HEADACHE; HUMAN; INTERNATIONAL NORMALIZED RATIO; ISOMER; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RASH; TIME TO REACH MAXIMUM PLASMA CONCENTRATION; TITRIMETRY;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; AREA UNDER CURVE; BLOOD COAGULATION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PENTOSAN SULFURIC POLYESTER; PROTHROMBIN TIME; WARFARIN;

EID: 23044465582     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005278600     Document Type: Article

References (27)

1. Parsons CL, Kamarei M, Monga M. Interstitial cystitis. In: Goldman MB, Hatch MC, eds. Women and Health. San Diego: Academic Press; 2000:1110-1119.
2. Koziol JA. Epidemiology of interstitial cystitis. Urol Clin North Am. 1994;21:7-71.
3. Miller JL, Bavendum TG, Berger RE. Interstitial cystitis in men. In: Sant GR, ed. Interstitial Cystitis. Philadelphia: Lippincott-Raven; 1997:165-167.
4. Bergqvist D, Efsing HO, Hallböök T, Lindblad B. Prevention of post-operative thromboembolic complications: a prospective comparison between Dextran 70, Dihydroorgostamin heparin and a sulphated polysaccharide. Ada Chir Scand. 1980;146:559-568.
5. Bergqvist D, Ljunger H. A comparative study of Dextran 70 and a sulphated polysaccharide in the prevention of postoperative thromboembolic complications. Br J Surg. 1981;68:449-451.
6. Bergqvist D, Lindblad B, Mätzsch T. Glycosaminoglycans in prophylaxis against venous thromboembolism. In: Lane DA, Bjork I, Lindahl U, eds. Heparin and Related Polysaccharides. New York: Plenum; 1992:259-274.
7. Soria C, Soria J, Rychewaert JJ, Holmer E, Caen JP. Anticoagulant activities of pentosane polysulphate: comparison with standard heparin and a fraction of low molecular weight heparin. Thromb Res. 1980;19:455-463.
8. Fellström B, Björklund U, Danielson BG, Eriksson H, Odlind B, Tengblad A. Pentosan polysulfate (ELMIRON®): pharmacokinetics and effects on the urinary inhibition of crystal growth. In: Vahlensieck W, Gassner G, eds. Pathogenese und Klinik der Harnsteine. Darmstadt, Germany: Steinkopff-Verlag; 1987:340-396.
9. Faaij RA, Srivastava N, van Griensven JMT, et al. The oral bioavailability of pentosan polysulfate sodium in healthy volunteers. Eur J Clin Pharmacol. 1999;54:929-935.
10. O'Reilly RA. Studies on the optical entiomorphs of warfarin in man. Clin Pharmacol Ther. 1974;6:348-354.
11. Lewis RJ, Trager WF, Chan KK, et al. Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest. 1974;53:1607-1617.
12. Koch-Weser J, Seller E. Drug interactions with coumarin anticoagulants (part I). N Engl J Med. 1971;285:487-498a.
13. Koch-Weser J, Seller E. Drug interactions with coumarin anticoagulants (part II). N Engl J Med. 1971;285:547-558b.
14. Hirsh J, Dalen JE, Deykin D, Poller L, Bussay H. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1995;108:23S-46S.
15. Hirsh J. Oral anticoagulant drugs. N Engl J Med. 1991;324:1865-1875.
16. Schuirman DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokin Biopharm. 1987;15:657-680.
17. Gibaldi M, Perrier G. Pharmacokinetlcs. 2nd ed. New York: Marcel Dekker; 1982.
18. Grind M, Murphy M, Warrington S, Aberf J. Method for studying drug-warfarin interactions. Clin Pharmacol Ther. 1993;54:381-387.
19. Yates RA, Wong J, Seiberling M, Merz M, März W, Nauck M. The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br J Clin Pharmacol. 2001;51:429-435.
20. Dingemanse J, Meyerhoff C, Schadrack J. Effect of the catechol-O-methyltransfernse inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin. Br J Clin Pharmacol. 2002;53:485-491.
21. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interaction of warfarin with drugs and food. Ann Intern Med. 1994;121:676-683.
22. Harris JE. Interaction of dietary factors with oral anticoagulants: review and applications. J Am Diet Assoc. 1995;95:580-584.
23. Cushman M, Booth SL, Possidente CJ, Davidson KW, Sadowski JA, Bovill EG. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol. 2001;112:572-577.
24. White RH, Zhou H, Romano P, Mungall D. Changes in warfarin levels and variations in steady-state prothrombin times. Clin Pharmacol Ther. 1995;58:588-593.
25. Faaij RA, Burggraaf J, Schoemaker RC, van Amsterdam RGM, Gohen AF. Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. Br J Clin Pharmacol. 2002;54:304-308.
26. Giedrojć J, Radziwon P, Klimiuk M, Bielawiec M, Breddin HK, Kloczko J. Experimental studies on the anticoagulant and antithrombotic effects of sodium and calcium pentosan polysulfate. J Physiol Pharmacol. 1999;50:111-119.
27. Giedrojć J, Klimiuk M, Radziwou P, Kloczko J, Bielawiec M, Breddin HK. Comparative study of the in vitro and in vivo activities of heparinoids derivative investigated on the animal model. J Cardiovasc Pharmacol. 1999;34:340-345.